| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 37 | 2020 | 1109 | 2.660 |
Why?
|
| Alcohol Drinking | 26 | 2018 | 805 | 1.760 |
Why?
|
| Naltrexone | 11 | 2020 | 195 | 1.440 |
Why?
|
| Corpus Striatum | 23 | 2011 | 279 | 1.190 |
Why?
|
| Cyclohexanecarboxylic Acids | 6 | 2013 | 60 | 1.000 |
Why?
|
| Amines | 6 | 2013 | 98 | 0.970 |
Why?
|
| Narcotic Antagonists | 8 | 2017 | 184 | 0.940 |
Why?
|
| gamma-Aminobutyric Acid | 7 | 2013 | 208 | 0.930 |
Why?
|
| Dopamine | 23 | 2010 | 474 | 0.820 |
Why?
|
| Aripiprazole | 4 | 2017 | 43 | 0.770 |
Why?
|
| Ethanol | 19 | 2017 | 893 | 0.750 |
Why?
|
| Antipsychotic Agents | 3 | 2017 | 247 | 0.630 |
Why?
|
| Stereotyped Behavior | 14 | 1993 | 42 | 0.610 |
Why?
|
| Apomorphine | 18 | 1995 | 48 | 0.600 |
Why?
|
| Substance Withdrawal Syndrome | 6 | 2013 | 435 | 0.590 |
Why?
|
| Self-Control | 1 | 2017 | 9 | 0.590 |
Why?
|
| Receptors, Dopamine | 13 | 1998 | 119 | 0.570 |
Why?
|
| Impulsive Behavior | 2 | 2017 | 85 | 0.570 |
Why?
|
| Cold Temperature | 2 | 2006 | 90 | 0.540 |
Why?
|
| Motor Activity | 10 | 2012 | 621 | 0.540 |
Why?
|
| GABA Modulators | 4 | 2013 | 26 | 0.530 |
Why?
|
| Adaptation, Psychological | 4 | 2013 | 447 | 0.520 |
Why?
|
| Behavior, Animal | 10 | 2012 | 470 | 0.500 |
Why?
|
| Cues | 10 | 2017 | 654 | 0.500 |
Why?
|
| Male | 88 | 2020 | 37321 | 0.460 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 5 | 2020 | 82 | 0.430 |
Why?
|
| Flumazenil | 5 | 2013 | 23 | 0.420 |
Why?
|
| Receptors, Opioid, mu | 5 | 2020 | 70 | 0.420 |
Why?
|
| Adult | 46 | 2018 | 21403 | 0.410 |
Why?
|
| Female | 64 | 2020 | 38074 | 0.370 |
Why?
|
| Lorazepam | 2 | 2009 | 54 | 0.370 |
Why?
|
| Depressive Disorder | 3 | 2004 | 621 | 0.340 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 9 | 2011 | 266 | 0.340 |
Why?
|
| Paroxetine | 4 | 2013 | 28 | 0.340 |
Why?
|
| Central Nervous System Depressants | 7 | 2017 | 182 | 0.310 |
Why?
|
| Substantia Nigra | 6 | 2010 | 102 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2015 | 1745 | 0.300 |
Why?
|
| Catechol O-Methyltransferase | 3 | 2020 | 31 | 0.300 |
Why?
|
| Alcohol Deterrents | 4 | 2018 | 86 | 0.300 |
Why?
|
| Appetitive Behavior | 1 | 2007 | 18 | 0.290 |
Why?
|
| Expressed Emotion | 1 | 2007 | 16 | 0.290 |
Why?
|
| Brain | 14 | 2017 | 2176 | 0.290 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2007 | 28 | 0.280 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2006 | 1506 | 0.280 |
Why?
|
| Touch | 1 | 2006 | 25 | 0.280 |
Why?
|
| Haloperidol | 9 | 1993 | 95 | 0.270 |
Why?
|
| Psychomotor Performance | 2 | 2006 | 213 | 0.270 |
Why?
|
| Humans | 57 | 2020 | 68618 | 0.270 |
Why?
|
| Smoking | 3 | 2018 | 1452 | 0.270 |
Why?
|
| Animals | 62 | 2017 | 20881 | 0.260 |
Why?
|
| Double-Blind Method | 12 | 2018 | 1738 | 0.250 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 2800 | 0.250 |
Why?
|
| Stress, Physiological | 1 | 2006 | 215 | 0.240 |
Why?
|
| Stress, Psychological | 3 | 2011 | 824 | 0.240 |
Why?
|
| Anxiety | 4 | 2014 | 422 | 0.240 |
Why?
|
| Sulpiride | 3 | 2001 | 20 | 0.230 |
Why?
|
| Synaptic Transmission | 7 | 2015 | 236 | 0.230 |
Why?
|
| Middle Aged | 25 | 2020 | 21147 | 0.230 |
Why?
|
| Receptors, Dopamine D2 | 7 | 2017 | 109 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 20 | 2016 | 2791 | 0.220 |
Why?
|
| Amphetamine | 3 | 2001 | 77 | 0.220 |
Why?
|
| Peer Group | 1 | 2004 | 104 | 0.220 |
Why?
|
| Hydroxydopamines | 8 | 1992 | 25 | 0.220 |
Why?
|
| Life Change Events | 1 | 2004 | 223 | 0.210 |
Why?
|
| Dopamine Antagonists | 2 | 2001 | 65 | 0.210 |
Why?
|
| Oxidopamine | 8 | 1993 | 42 | 0.210 |
Why?
|
| Nucleus Accumbens | 6 | 2015 | 417 | 0.200 |
Why?
|
| Mice | 28 | 2016 | 8474 | 0.200 |
Why?
|
| Rats | 31 | 2015 | 5300 | 0.190 |
Why?
|
| Severity of Illness Index | 8 | 2017 | 1851 | 0.190 |
Why?
|
| Social Support | 1 | 2004 | 423 | 0.190 |
Why?
|
| Parents | 1 | 2004 | 312 | 0.190 |
Why?
|
| Treatment Outcome | 13 | 2020 | 7029 | 0.180 |
Why?
|
| Depressive Disorder, Major | 2 | 2007 | 439 | 0.180 |
Why?
|
| Spiperone | 8 | 1993 | 29 | 0.180 |
Why?
|
| Brain Mapping | 7 | 2017 | 532 | 0.180 |
Why?
|
| Glycerophospholipids | 2 | 2009 | 20 | 0.170 |
Why?
|
| Neostriatum | 3 | 2010 | 60 | 0.170 |
Why?
|
| Adolescent | 10 | 2018 | 8912 | 0.170 |
Why?
|
| Drug Therapy, Combination | 5 | 2013 | 649 | 0.170 |
Why?
|
| Rats, Sprague-Dawley | 19 | 2003 | 2083 | 0.160 |
Why?
|
| Depression | 2 | 2008 | 943 | 0.160 |
Why?
|
| Quinolones | 2 | 2010 | 60 | 0.160 |
Why?
|
| Phobic Disorders | 3 | 2013 | 227 | 0.160 |
Why?
|
| Young Adult | 9 | 2018 | 5717 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2017 | 2223 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 3259 | 0.150 |
Why?
|
| Reward | 3 | 2017 | 201 | 0.150 |
Why?
|
| Piperazines | 2 | 2010 | 206 | 0.150 |
Why?
|
| Motivation | 5 | 2017 | 561 | 0.150 |
Why?
|
| Combat Disorders | 2 | 1995 | 102 | 0.150 |
Why?
|
| Neurons | 7 | 2015 | 881 | 0.150 |
Why?
|
| Dopamine Agonists | 1 | 2017 | 68 | 0.150 |
Why?
|
| Limbic System | 2 | 1995 | 106 | 0.140 |
Why?
|
| Synapses | 2 | 2017 | 222 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 2 | 2017 | 290 | 0.140 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2006 | 106 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2010 | 154 | 0.130 |
Why?
|
| Secondary Prevention | 3 | 2013 | 291 | 0.130 |
Why?
|
| Potassium Channels | 1 | 2016 | 55 | 0.130 |
Why?
|
| Craving | 2 | 2017 | 200 | 0.130 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 47 | 0.130 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 1995 | 7 | 0.130 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 189 | 0.130 |
Why?
|
| Reflex, Startle | 3 | 2007 | 39 | 0.130 |
Why?
|
| Cocaine-Related Disorders | 2 | 2013 | 504 | 0.130 |
Why?
|
| Hypertension | 3 | 2009 | 1535 | 0.130 |
Why?
|
| Inhalant Abuse | 1 | 2015 | 7 | 0.130 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 4 | 2009 | 27 | 0.120 |
Why?
|
| Aging | 6 | 2010 | 911 | 0.120 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2015 | 27 | 0.120 |
Why?
|
| Social Environment | 2 | 2012 | 182 | 0.120 |
Why?
|
| Long-Term Synaptic Depression | 1 | 2015 | 32 | 0.120 |
Why?
|
| Hydrocortisone | 2 | 2006 | 291 | 0.120 |
Why?
|
| Nicotine | 1 | 2018 | 350 | 0.120 |
Why?
|
| Toluene | 1 | 2015 | 37 | 0.120 |
Why?
|
| Neural Inhibition | 1 | 2015 | 80 | 0.120 |
Why?
|
| Solvents | 1 | 2015 | 109 | 0.120 |
Why?
|
| Benzazepines | 2 | 2014 | 104 | 0.120 |
Why?
|
| Taurine | 2 | 2013 | 51 | 0.120 |
Why?
|
| Extracellular Space | 4 | 2010 | 121 | 0.120 |
Why?
|
| Hippocampus | 5 | 1998 | 471 | 0.120 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 274 | 0.110 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2013 | 128 | 0.110 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 1293 | 0.110 |
Why?
|
| Quinoxalines | 1 | 2014 | 78 | 0.110 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 79 | 0.110 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2013 | 13 | 0.110 |
Why?
|
| Substance-Related Disorders | 3 | 2015 | 1242 | 0.110 |
Why?
|
| Executive Function | 1 | 2014 | 106 | 0.110 |
Why?
|
| Social Behavior Disorders | 1 | 2013 | 16 | 0.110 |
Why?
|
| Nicotinic Agonists | 1 | 2014 | 111 | 0.110 |
Why?
|
| Anxiety Disorders | 3 | 2013 | 426 | 0.110 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2013 | 54 | 0.110 |
Why?
|
| Glucuronates | 1 | 2012 | 19 | 0.110 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2012 | 27 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2008 | 1451 | 0.100 |
Why?
|
| Hair | 1 | 2012 | 46 | 0.100 |
Why?
|
| Extinction, Psychological | 1 | 2014 | 240 | 0.100 |
Why?
|
| Aged | 9 | 2018 | 14862 | 0.100 |
Why?
|
| Models, Psychological | 2 | 2011 | 180 | 0.100 |
Why?
|
| Bromocriptine | 2 | 1990 | 8 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 567 | 0.100 |
Why?
|
| Frontal Lobe | 3 | 2005 | 156 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2012 | 220 | 0.100 |
Why?
|
| Microdialysis | 5 | 2010 | 147 | 0.100 |
Why?
|
| Methylphenidate | 1 | 2012 | 97 | 0.100 |
Why?
|
| Dizocilpine Maleate | 3 | 2003 | 43 | 0.100 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 640 | 0.100 |
Why?
|
| Photic Stimulation | 3 | 2008 | 229 | 0.090 |
Why?
|
| Arousal | 3 | 1995 | 168 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2015 | 1040 | 0.090 |
Why?
|
| Conditioning, Operant | 5 | 2015 | 241 | 0.090 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2010 | 71 | 0.090 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2010 | 52 | 0.090 |
Why?
|
| Acetylcysteine | 1 | 2013 | 296 | 0.090 |
Why?
|
| Drug Interactions | 5 | 2018 | 289 | 0.090 |
Why?
|
| Time Factors | 11 | 2010 | 4655 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 1 | 2010 | 102 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2010 | 124 | 0.080 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 2077 | 0.080 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2006 | 150 | 0.080 |
Why?
|
| Affect | 2 | 2008 | 218 | 0.080 |
Why?
|
| Electroencephalography | 2 | 1991 | 418 | 0.080 |
Why?
|
| Shyness | 1 | 2009 | 10 | 0.080 |
Why?
|
| Receptors, Dopamine D1 | 3 | 1996 | 87 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 237 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2005 | 320 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 1 | 2009 | 96 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2008 | 4848 | 0.080 |
Why?
|
| Hypothalamus | 3 | 2006 | 78 | 0.080 |
Why?
|
| Triiodobenzoic Acids | 1 | 2008 | 28 | 0.080 |
Why?
|
| Ondansetron | 1 | 2008 | 13 | 0.080 |
Why?
|
| Linear Models | 4 | 2015 | 521 | 0.080 |
Why?
|
| Dopamine D2 Receptor Antagonists | 2 | 2001 | 13 | 0.080 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 31 | 0.080 |
Why?
|
| Basal Ganglia | 1 | 2008 | 45 | 0.080 |
Why?
|
| Comorbidity | 4 | 2007 | 1426 | 0.080 |
Why?
|
| Iohexol | 1 | 2008 | 82 | 0.080 |
Why?
|
| Narcotics | 1 | 2008 | 65 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2007 | 402 | 0.080 |
Why?
|
| Veterans | 1 | 1995 | 904 | 0.080 |
Why?
|
| Self Administration | 3 | 2017 | 419 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2010 | 297 | 0.070 |
Why?
|
| Pharmacogenomic Variants | 2 | 2017 | 15 | 0.070 |
Why?
|
| Creatinine | 1 | 2008 | 243 | 0.070 |
Why?
|
| Audiovisual Aids | 1 | 2007 | 20 | 0.070 |
Why?
|
| Genotype | 4 | 2020 | 786 | 0.070 |
Why?
|
| Pregnancy | 10 | 2010 | 2334 | 0.070 |
Why?
|
| Brain Chemistry | 3 | 2004 | 173 | 0.070 |
Why?
|
| Behavior, Addictive | 1 | 2010 | 317 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2009 | 193 | 0.070 |
Why?
|
| Self Disclosure | 1 | 2007 | 55 | 0.070 |
Why?
|
| Cognition | 1 | 2011 | 513 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 274 | 0.070 |
Why?
|
| Affective Symptoms | 1 | 2007 | 50 | 0.070 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2007 | 30 | 0.070 |
Why?
|
| Prolactin | 1 | 1987 | 61 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2006 | 3705 | 0.070 |
Why?
|
| Electromyography | 1 | 2007 | 184 | 0.070 |
Why?
|
| Immersion | 1 | 2006 | 10 | 0.070 |
Why?
|
| Pituitary Gland | 1 | 2006 | 29 | 0.070 |
Why?
|
| Adrenal Glands | 1 | 2006 | 46 | 0.070 |
Why?
|
| Receptors, GABA-A | 3 | 1995 | 89 | 0.070 |
Why?
|
| Potassium | 3 | 2010 | 168 | 0.070 |
Why?
|
| Body Weight | 4 | 2010 | 554 | 0.070 |
Why?
|
| Self Mutilation | 1 | 1986 | 2 | 0.070 |
Why?
|
| Grooming | 1 | 1986 | 5 | 0.070 |
Why?
|
| Models, Biological | 4 | 1997 | 981 | 0.070 |
Why?
|
| Alcohol-Related Disorders | 1 | 2007 | 95 | 0.070 |
Why?
|
| Pituitary-Adrenal System | 1 | 2006 | 138 | 0.070 |
Why?
|
| Catalepsy | 1 | 1985 | 8 | 0.070 |
Why?
|
| DNA | 1 | 2008 | 597 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2005 | 498 | 0.060 |
Why?
|
| Biomarkers | 3 | 2018 | 1593 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 951 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2008 | 384 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2008 | 307 | 0.060 |
Why?
|
| Calcium | 5 | 1997 | 929 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2009 | 468 | 0.060 |
Why?
|
| Data Collection | 2 | 2008 | 420 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 627 | 0.060 |
Why?
|
| Sleep | 3 | 2009 | 263 | 0.060 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2003 | 11 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 1174 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2005 | 183 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2013 | 782 | 0.060 |
Why?
|
| Pyrazoles | 2 | 2015 | 190 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2003 | 56 | 0.060 |
Why?
|
| Reaction Time | 2 | 1993 | 170 | 0.050 |
Why?
|
| N-Methylaspartate | 4 | 2015 | 59 | 0.050 |
Why?
|
| Gene Expression | 1 | 2005 | 770 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2003 | 93 | 0.050 |
Why?
|
| Body Image | 1 | 2004 | 100 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2011 | 1692 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 562 | 0.050 |
Why?
|
| Tobacco Use Disorder | 1 | 2007 | 432 | 0.050 |
Why?
|
| Feeding and Eating Disorders | 1 | 2004 | 106 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2009 | 334 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 767 | 0.050 |
Why?
|
| Psychological Tests | 2 | 2013 | 96 | 0.050 |
Why?
|
| Glutamic Acid | 3 | 2015 | 332 | 0.050 |
Why?
|
| Temperance | 2 | 2013 | 41 | 0.050 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2001 | 12 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 319 | 0.050 |
Why?
|
| Reinforcement Schedule | 2 | 2014 | 59 | 0.050 |
Why?
|
| Cerebral Cortex | 4 | 2003 | 415 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2015 | 1664 | 0.050 |
Why?
|
| Glutathione | 2 | 1993 | 343 | 0.050 |
Why?
|
| Animals, Newborn | 3 | 1996 | 396 | 0.050 |
Why?
|
| Mesencephalon | 2 | 1995 | 41 | 0.050 |
Why?
|
| Feeding Behavior | 2 | 1984 | 224 | 0.040 |
Why?
|
| Injections | 2 | 1993 | 119 | 0.040 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2013 | 151 | 0.040 |
Why?
|
| Rotation | 2 | 1993 | 58 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 546 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 931 | 0.040 |
Why?
|
| Neural Pathways | 4 | 1995 | 324 | 0.040 |
Why?
|
| Risk Factors | 3 | 2008 | 5731 | 0.040 |
Why?
|
| Protein Binding | 3 | 2012 | 1027 | 0.040 |
Why?
|
| Prosencephalon | 1 | 1998 | 38 | 0.040 |
Why?
|
| Age Factors | 4 | 2010 | 1864 | 0.040 |
Why?
|
| Smoking Cessation | 1 | 2007 | 1034 | 0.040 |
Why?
|
| Enkephalins | 2 | 2015 | 89 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2018 | 24 | 0.040 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2017 | 10 | 0.040 |
Why?
|
| Minisatellite Repeats | 1 | 2017 | 16 | 0.040 |
Why?
|
| Microinjections | 2 | 2015 | 130 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 2279 | 0.040 |
Why?
|
| Memory | 2 | 1995 | 214 | 0.040 |
Why?
|
| Muscimol | 2 | 1995 | 26 | 0.040 |
Why?
|
| Alcoholic Intoxication | 1 | 1998 | 61 | 0.040 |
Why?
|
| Drinking Behavior | 1 | 1977 | 20 | 0.040 |
Why?
|
| Recurrence | 2 | 2011 | 948 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2015 | 765 | 0.040 |
Why?
|
| Transferrin | 1 | 2018 | 94 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2017 | 31 | 0.040 |
Why?
|
| Species Specificity | 3 | 1987 | 303 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2014 | 1342 | 0.040 |
Why?
|
| Sex Characteristics | 2 | 2010 | 295 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2008 | 257 | 0.030 |
Why?
|
| Phenylenediamines | 1 | 2016 | 16 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 249 | 0.030 |
Why?
|
| Membrane Transport Modulators | 1 | 2016 | 23 | 0.030 |
Why?
|
| Calcium Channel Blockers | 2 | 1996 | 138 | 0.030 |
Why?
|
| Mice, Inbred CBA | 2 | 1987 | 107 | 0.030 |
Why?
|
| Discrimination Learning | 1 | 1976 | 45 | 0.030 |
Why?
|
| Calcium Channels | 1 | 1996 | 59 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2016 | 120 | 0.030 |
Why?
|
| Carbamates | 1 | 2016 | 41 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 55 | 0.030 |
Why?
|
| Avoidance Learning | 3 | 1993 | 58 | 0.030 |
Why?
|
| Visual Perception | 1 | 2017 | 124 | 0.030 |
Why?
|
| Vietnam | 1 | 1995 | 36 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 1996 | 223 | 0.030 |
Why?
|
| Thalamus | 1 | 1995 | 82 | 0.030 |
Why?
|
| Child Abuse, Sexual | 1 | 1997 | 150 | 0.030 |
Why?
|
| Estrus | 2 | 1987 | 14 | 0.030 |
Why?
|
| Apamin | 1 | 2015 | 13 | 0.030 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2015 | 21 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 1987 | 532 | 0.030 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 32 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 35 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1995 | 121 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 79 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 63 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2015 | 166 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2015 | 105 | 0.030 |
Why?
|
| Child Abuse | 1 | 1997 | 186 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 381 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2015 | 204 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2015 | 68 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2015 | 85 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2015 | 218 | 0.030 |
Why?
|
| Medial Forebrain Bundle | 1 | 1993 | 3 | 0.030 |
Why?
|
| Fetus | 1 | 1994 | 157 | 0.030 |
Why?
|
| Thalamic Nuclei | 1 | 1994 | 9 | 0.030 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2014 | 51 | 0.030 |
Why?
|
| Central Nervous System Agents | 1 | 2014 | 37 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 3 | 2000 | 89 | 0.030 |
Why?
|
| Maze Learning | 1 | 2014 | 138 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 187 | 0.030 |
Why?
|
| Globus Pallidus | 1 | 1993 | 64 | 0.030 |
Why?
|
| Rats, Long-Evans | 1 | 2014 | 203 | 0.030 |
Why?
|
| Rats, Inbred Strains | 3 | 1992 | 532 | 0.030 |
Why?
|
| Varenicline | 1 | 2014 | 98 | 0.030 |
Why?
|
| Mice, Inbred Strains | 2 | 1992 | 181 | 0.030 |
Why?
|
| Computational Biology | 1 | 2015 | 190 | 0.030 |
Why?
|
| omega-Conotoxins | 1 | 1993 | 1 | 0.030 |
Why?
|
| Vagina | 2 | 2005 | 88 | 0.030 |
Why?
|
| Benzamides | 1 | 2014 | 156 | 0.030 |
Why?
|
| Logistic Models | 2 | 2009 | 1420 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2013 | 85 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 1993 | 35 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 13 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2014 | 211 | 0.030 |
Why?
|
| Substance Abuse Detection | 1 | 2012 | 66 | 0.030 |
Why?
|
| Kinetics | 4 | 1992 | 1047 | 0.030 |
Why?
|
| Denervation | 1 | 1992 | 23 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2008 | 737 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 2093 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 947 | 0.020 |
Why?
|
| Reflex, Righting | 1 | 2011 | 4 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2013 | 210 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 392 | 0.020 |
Why?
|
| Drug-Seeking Behavior | 1 | 2014 | 213 | 0.020 |
Why?
|
| Beer | 1 | 2011 | 6 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 301 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 1991 | 31 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 329 | 0.020 |
Why?
|
| Glycine | 3 | 1997 | 89 | 0.020 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2010 | 9 | 0.020 |
Why?
|
| Electrophysiology | 1 | 1991 | 160 | 0.020 |
Why?
|
| Injections, Intraventricular | 2 | 1993 | 50 | 0.020 |
Why?
|
| Synaptic Vesicles | 1 | 2010 | 18 | 0.020 |
Why?
|
| Electrodes, Implanted | 1 | 1991 | 98 | 0.020 |
Why?
|
| Synaptosomes | 1 | 2010 | 57 | 0.020 |
Why?
|
| Heterozygote | 1 | 2010 | 174 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 260 | 0.020 |
Why?
|
| Binding, Competitive | 2 | 1992 | 165 | 0.020 |
Why?
|
| Postural Balance | 1 | 2010 | 93 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1054 | 0.020 |
Why?
|
| Serine | 2 | 2003 | 99 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 448 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1038 | 0.020 |
Why?
|
| Functional Laterality | 2 | 1995 | 240 | 0.020 |
Why?
|
| Reference Values | 1 | 1990 | 579 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 507 | 0.020 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 221 | 0.020 |
Why?
|
| Tritium | 2 | 2003 | 101 | 0.020 |
Why?
|
| Amnesia | 1 | 1968 | 17 | 0.020 |
Why?
|
| Social Control, Informal | 1 | 2008 | 8 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1033 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2010 | 455 | 0.020 |
Why?
|
| GTP-Binding Proteins | 2 | 1990 | 231 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 411 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2008 | 134 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2004 | 1046 | 0.020 |
Why?
|
| Hypothermia, Induced | 1 | 1968 | 93 | 0.020 |
Why?
|
| Methods | 1 | 1988 | 156 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 626 | 0.020 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2008 | 71 | 0.020 |
Why?
|
| Inservice Training | 1 | 2008 | 68 | 0.020 |
Why?
|
| Pseudopregnancy | 1 | 1987 | 1 | 0.020 |
Why?
|
| Dihydroergotoxine | 1 | 1987 | 4 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 492 | 0.020 |
Why?
|
| Patient Participation | 1 | 2009 | 146 | 0.020 |
Why?
|
| Levodopa | 1 | 1987 | 12 | 0.020 |
Why?
|
| Probability | 1 | 1988 | 245 | 0.020 |
Why?
|
| Estrous Cycle | 1 | 2007 | 23 | 0.020 |
Why?
|
| Individuality | 1 | 2007 | 44 | 0.020 |
Why?
|
| Pituitary Gland, Anterior | 1 | 1987 | 10 | 0.020 |
Why?
|
| Perfusion | 2 | 1997 | 131 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 195 | 0.020 |
Why?
|
| Community Health Services | 1 | 2008 | 141 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 572 | 0.020 |
Why?
|
| Calmodulin | 1 | 1987 | 53 | 0.020 |
Why?
|
| Social Behavior | 1 | 2007 | 164 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2009 | 340 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2008 | 296 | 0.020 |
Why?
|
| Progesterone | 1 | 1987 | 115 | 0.020 |
Why?
|
| Oxygen | 1 | 2008 | 386 | 0.020 |
Why?
|
| Chlorpromazine | 1 | 1985 | 7 | 0.020 |
Why?
|
| Norepinephrine | 2 | 1977 | 276 | 0.020 |
Why?
|
| Domperidone | 1 | 1985 | 11 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2009 | 335 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2005 | 15 | 0.020 |
Why?
|
| Afferent Pathways | 2 | 1983 | 31 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 592 | 0.020 |
Why?
|
| Choline O-Acetyltransferase | 1 | 1985 | 30 | 0.020 |
Why?
|
| 2-Amino-5-phosphonovalerate | 2 | 1997 | 9 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2008 | 867 | 0.020 |
Why?
|
| Prevalence | 1 | 2009 | 1619 | 0.020 |
Why?
|
| Contrast Media | 1 | 2008 | 595 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 498 | 0.010 |
Why?
|
| Culture Techniques | 2 | 1995 | 65 | 0.010 |
Why?
|
| Fenfluramine | 1 | 1984 | 6 | 0.010 |
Why?
|
| Myelin Sheath | 1 | 2004 | 115 | 0.010 |
Why?
|
| Spermidine | 1 | 2003 | 21 | 0.010 |
Why?
|
| Dextroamphetamine | 1 | 1984 | 30 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2003 | 80 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 68 | 0.010 |
Why?
|
| Kainic Acid | 1 | 1983 | 44 | 0.010 |
Why?
|
| Multigene Family | 1 | 2003 | 93 | 0.010 |
Why?
|
| Binding Sites | 1 | 1985 | 631 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2003 | 93 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2550 | 0.010 |
Why?
|
| Piperidines | 1 | 2003 | 123 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 710 | 0.010 |
Why?
|
| Glutathione Disulfide | 2 | 1993 | 31 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2004 | 307 | 0.010 |
Why?
|
| Psychometrics | 1 | 2005 | 514 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 1553 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 1196 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 1200 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 659 | 0.010 |
Why?
|
| Child | 2 | 2004 | 6405 | 0.010 |
Why?
|
| Pyrrolidinones | 1 | 1997 | 15 | 0.010 |
Why?
|
| Kynurenic Acid | 1 | 1997 | 26 | 0.010 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 1997 | 59 | 0.010 |
Why?
|
| Allosteric Regulation | 1 | 1997 | 58 | 0.010 |
Why?
|
| Dominance, Cerebral | 1 | 1997 | 65 | 0.010 |
Why?
|
| Association | 1 | 1976 | 5 | 0.010 |
Why?
|
| Maternal Deprivation | 1 | 1976 | 4 | 0.010 |
Why?
|
| Cerebellum | 1 | 1997 | 103 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1996 | 62 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1996 | 200 | 0.010 |
Why?
|
| Social Isolation | 1 | 1976 | 40 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 1995 | 15 | 0.010 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 1995 | 27 | 0.010 |
Why?
|
| Picrotoxin | 1 | 1995 | 14 | 0.010 |
Why?
|
| Central Nervous System | 1 | 1976 | 107 | 0.010 |
Why?
|
| GABA Antagonists | 1 | 1995 | 22 | 0.010 |
Why?
|
| Receptors, Phencyclidine | 1 | 1995 | 1 | 0.010 |
Why?
|
| Synaptic Membranes | 1 | 1995 | 8 | 0.010 |
Why?
|
| Caudate Nucleus | 1 | 1995 | 56 | 0.010 |
Why?
|
| Lactation | 1 | 1976 | 110 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 1995 | 56 | 0.010 |
Why?
|
| Eating | 1 | 1975 | 119 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1995 | 119 | 0.010 |
Why?
|
| Social Class | 1 | 1995 | 127 | 0.010 |
Why?
|
| Temperature | 1 | 1976 | 341 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1995 | 137 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1995 | 125 | 0.010 |
Why?
|
| Educational Status | 1 | 1995 | 273 | 0.010 |
Why?
|
| Magnesium | 1 | 1994 | 110 | 0.010 |
Why?
|
| Schizophrenia | 1 | 1995 | 206 | 0.010 |
Why?
|
| Analgesics | 1 | 1995 | 118 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 1753 | 0.010 |
Why?
|
| Sleep Stages | 1 | 1993 | 30 | 0.010 |
Why?
|
| Tremor | 1 | 1993 | 16 | 0.010 |
Why?
|
| Cytosol | 1 | 1993 | 123 | 0.010 |
Why?
|
| Acoustic Stimulation | 1 | 1993 | 206 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1992 | 57 | 0.010 |
Why?
|
| Cell Line | 1 | 1996 | 1752 | 0.010 |
Why?
|
| United States | 1 | 2004 | 7367 | 0.010 |
Why?
|
| Strychnine | 1 | 1991 | 14 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1996 | 2673 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1990 | 29 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1992 | 567 | 0.010 |
Why?
|
| Electroshock | 1 | 1968 | 36 | 0.010 |
Why?
|
| Ovulation | 1 | 1987 | 10 | 0.000 |
Why?
|
| Carbidopa | 1 | 1987 | 3 | 0.000 |
Why?
|
| Silicone Elastomers | 1 | 1987 | 17 | 0.000 |
Why?
|
| Membranes | 1 | 1987 | 26 | 0.000 |
Why?
|
| Catecholamines | 1 | 1984 | 73 | 0.000 |
Why?
|
| Receptors, Serotonin | 1 | 1984 | 74 | 0.000 |
Why?
|
| Leukocytes | 1 | 1982 | 99 | 0.000 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1981 | 153 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 1982 | 431 | 0.000 |
Why?
|
| Hypothalamus, Middle | 1 | 1975 | 4 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1975 | 218 | 0.000 |
Why?
|